Copyright
©The Author(s) 2015.
World J Gastroenterol. Nov 28, 2015; 21(44): 12558-12575
Published online Nov 28, 2015. doi: 10.3748/wjg.v21.i44.12558
Published online Nov 28, 2015. doi: 10.3748/wjg.v21.i44.12558
Table 3 Immunomodulators in pipeline for hepatitis B virus treatment
Immune enhancer | Function | Developer | Phase |
CYT-107 | Recombinant IL-7 | Cytheris SA, France | Phase II |
TG-1050 | Adenovirus based targeted immunotherapy | Transgene SA, France | Pre-clinical |
GS-9620 | TLR-7 agonist | Gilead Sciences, United States | Phase II |
GC1102 | Monoclonal antibodyRecombinant HBIg | Green Cross Corporation, Japan | Phase II |
CYT-003 | TLR-9 agonist | Tekmira Pharmaceuticals Corporation, Canada | Pre-clinical (Phase II for Asthma) |
SB 9200 | RIG-I and NOD2 activator | Spring Bank Pharmaceuticals, United States | Phase II |
- Citation: Manzoor S, Saalim M, Imran M, Resham S, Ashraf J. Hepatitis B virus therapy: What’s the future holding for us? World J Gastroenterol 2015; 21(44): 12558-12575
- URL: https://www.wjgnet.com/1007-9327/full/v21/i44/12558.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i44.12558